Clinigen said today it has acquired the cancer chemotherapy-reversing agent Totect® (dexrazoxane) from Biocodex USA for an undisclosed price, in a deal that expands the buyer’s operations into the U.S. market.

The deal also makes Clinigen the sole global supplier of dexrazoxane, indicated to reverse the toxic effects of anthracycline anti-cancer treatment.

In addition to Totect, the first and only FDA-approved treatment for anthracycline extravasation, Clinigen also markets Savene®, which the company acquired in 2014 from Norgine affiliate SpePharm for an undisclosed price, and Cardioxane®, an oncology support therapy acquired in 2013 from Novartis for $33 million.

Clinigen added that the acquisition also positioned the company to extend its products into additional indications, including cardioprotection.

Clinigen acquired Totect for an upfront payment and milestone-based installment payments over 12 months. Clinigen’s Specialty Pharmaceuticals division will oversee Totect’s® manufacturing, registration, distribution, and commercialization in the U.S. The division acquires global rights to—then works to revitalize and market—its own portfolio of niche hospital commercial products.

Totect is Clinigen’s sixth specialty treatment acquisition since the company was established in 2010.

“This product is a valuable addition to our global dexrazoxane portfolio and another step forward in our specialty pharmaceutical business strategy,” Clinigen CEO Peter George said in a statement.

Separately today, Clinigen released half-year results showing the company finished the second half of 2015 with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of £23.5 million (about $33 million), up 74% from a year earlier, in large part reflecting a scale-up of operations resulting from the Idis and Link Healthcare acquisitions last year.